Protagonist Therapeutics, Inc.

NasdaqGM:PTGX 株式レポート

時価総額：US$2.6b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Protagonist Therapeutics マネジメント

マネジメント 基準チェック /44

Protagonist Therapeutics'の CEO はDinesh Patelで、 Dec2008年に任命され、 の在任期間は 15.67年です。 の年間総報酬は$ 7.07Mで、 9.3%給与と90.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.71%を直接所有しており、その価値は$ 17.41M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と9.6年です。

主要情報

Dinesh Patel

最高経営責任者

US$7.1m

報酬総額

CEO給与比率9.3%
CEO在任期間15.8yrs
CEOの所有権0.7%
経営陣の平均在職期間3.7yrs
取締役会の平均在任期間9.7yrs

経営陣の近況

Recent updates

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06
An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15
We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21
This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

Protagonist EPS beats by $0.03, beats on revenue

May 04

CEO報酬分析

Protagonist Therapeutics の収益と比較して、Dinesh Patel の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Sep 30 2019n/an/a

-US$74m

Jun 30 2019n/an/a

-US$66m

Mar 31 2019n/an/a

-US$45m

Dec 31 2018US$4mUS$520k

-US$39m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$24m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$790kUS$475k

-US$37m

報酬と市場: Dineshの 総報酬 ($USD 7.07M ) は、 US市場 ($USD 6.75M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Dineshの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dinesh Patel (67 yo)

15.8yrs

在職期間

US$7,067,572

報酬

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He served as Interim Chief Financ...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Dinesh Patel
CEO, President15.8yrsUS$7.07m0.71%
$ 18.7m
Asif Ali
Executive VP & Chief Financial Officer2.4yrsUS$1.40m0%
$ 0
Suneel Gupta
Chief Development Officer5.7yrsUS$2.22m0.25%
$ 6.6m
Mark Smythe
Founder & VP Technology3.7yrsデータなしデータなし
Mohammad Masjedizadeh
Executive VP & Chief Technical Officer3.7yrsデータなしデータなし
Matthew Gosling
Executive VP & General Counsel4yrsデータなしデータなし
Carena Spivey
Head of HR & Senior VP of Human Resources3.7yrsデータなしデータなし
Ashok Bhandari
Executive VP & Chief Drug Discovery and Preclinical Development Officer3.7yrsデータなしデータなし
Carter King
Executive Vice President of Business Development3.4yrsデータなしデータなし
Abha Bommireddi
Executive Vice President of Portfolio & Program Management3.7yrsデータなしデータなし
Arturo Molina
Chief Medical Officer1.8yrsデータなし0.0069%
$ 181.6k
Samuel Saks
Clinical Development Advisor3.7yrsデータなしデータなし

3.7yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: PTGXの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Dinesh Patel
CEO, President15.8yrsUS$7.07m0.71%
$ 18.7m
Harlan Weisman
Clinical Advisor9.7yrsデータなしデータなし
Lewis Williams
Independent Director7.3yrsUS$351.52k0%
$ 0
Chaitan Khosla
Chairman of Scientific Advisory Board9.7yrsUS$188.07kデータなし
Harold Selick
Independent Chairman15.6yrsUS$395.27k0.048%
$ 1.2m
William Waddill
Independent Director8.2yrsUS$364.02k0.020%
$ 534.7k
Charles Craik
Scientific Advisorno dataデータなしデータなし
Mark Gallop
Scientific Advisorno dataデータなしデータなし
Wayne Lencer
Clinical Advisorno dataデータなしデータなし
Aida Habtezion
Clinical Advisorno dataデータなしデータなし
Ellen Scherl
Clinical Advisorno dataデータなしデータなし
Bryan Giraudo
Independent Director6.3yrsUS$356.52k0.031%
$ 802.1k

9.7yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: PTGXの 取締役会 は 経験豊富 であると考えられます ( 9.6年の平均在任期間)。